Depression in patients with epilepsy: screening, diagnosis and management
##plugins.themes.academic_pro.article.main##
Abstract
Abstract
Depression is the most frequent psychiatric comorbidity in epilepsy patients with a considerable impact on quality of life and a poor prognosis for the response to pharmacological and surgical treatments. The relationship between depression and epilepsy is bidirectional, involving common pathophysiogenic mechanisms. Despite its frequency and its negative impact on the natural course of the epileptic disease, depression is still underdiagnosed and insufficiently treated in these patients. This may be due to the lack of specific training of neurologists for the detection and management of psychiatric comorbidities, or even to the atypical clinical presentation of depressive symptoms in these patients. The management of depression in epileptics is both pharmacological and non-pharmacological, the main objective being to achieve complete remission of depressive symptoms without reducing seizure threshold. This article aims to describe the epidemiological, clinical and therapeutic aspects of depression in patients with epilepsy, in the light of the most recent data in the literature.
Keywords:
depression, epilepsy, comorbidity, NDDI-E, treatment.##plugins.themes.academic_pro.article.details##
References
- 1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55:475-82 2. Fiest KM, Dykeman J, Patten SB. Depression in epilepsy: a systematic review and meta-analysis. Neurology 2013;80(6):590-9 3. Tao K, Wang X. The comorbidity of epilepsy and depression: diagnosis and treatment. Exp Rev Neurother. 2016;16:1321-33 4. Siarava E, Hyphantis T, Katsanos AH, Pelidou SH, Kyritsis AP, Markoula S. Depression and quality of life in patients with epilepsy in Northwest Greece. Seizure. 2019;66:93-98. doi:10.1016/j.seizure.2019.02.012 5. Gnanavel S. Epilepsy and Depression: A Bidirectional Relationship. J Neurosci Rural Pract. 2017;8(Suppl 1):S5-S6 6. Theodore WH. Epilepsy and depression: imaging potential common factors. Clin EEG Neurosci. 2004;35(1):38-45. doi:10.1177/155005940403500110 7. Kondziella D, Asztely F. Don't be afraid to treat depression in patients with epilepsy!. Acta Neurol Scand. 2009;119(2):75-80. doi:10.1111/j.1600-0404.2008.01088.x 8. Mula M. Depression in epilepsy. Curr Opin Neurol. 2017;30(2):180-186. doi:10.1097/WCO.0000000000000431 9. Sylla M, Vogel AC, Bah AK. Prevalence, severity, and associations of depression in people with epilepsy in Guinea: A single-center study. Epilepsy Behav. 2020;113:107475. doi:10.1016/j.yebeh.2020.107475 10. Viguera AC, Fan Y, Thompson NR. Prevalence and Predictors of Depression Among Patients With Epilepsy, Stroke, and Multiple Sclerosis Using the Cleveland Clinic Knowledge Program Within the Neurological Institute. Psychosomatics. 2018;59(4):369-378. doi:10.1016/j.psym.2017.12.003. 11. Forthoffer N, Kleitz C, Bilger M, Brissart H. Depression could modulate neuropsychological status in epilepsy. Rev Neurol (Paris). 2020;176(6):456-467. doi:10.1016/j.neurol.2020.03.015 12. Zapata Barco AM, Restrepo-MartÃnez M, Restrepo D. Depression in People with Epilepsy. What is the Connection?. Depresión en personas con epilepsia. ¿Cuál es la conexión?. Rev Colomb Psiquiatr. 2020;49(1):53-61. doi:10.1016/j.rcp.2017.10.004 13. Zis P, Yfanti P, Siatouni A, Tavernarakis A, Gatzonis S. Determinants of depression among patients with epilepsy in Athens, Greece. Epilepsy Behav. 2014;33:106-109. doi:10.1016/j.yebeh.2014.02.024 14. Chentouf A, Zerfa I, Oubaiche ML. Facteurs de risque de dépression chez les épileptiques suivis au CHU d'Oran. El Hakim. 2018;9:40-49 15. Yang Y, Yang M, Shi Q, Wang T, Jiang M. Risk factors for depression in patients with epilepsy: A meta-analysis. Epilepsy Behav. 2020;106:107030. doi:10.1016/j.yebeh.2020.107030 16. Pope RA, Thompson PJ, Rantell K, Stretton J, Wright MA, Foong J. Frontal lobe dysfunction as a predictor of depression and anxiety following temporal lobe epilepsy surgery. Epilepsy Res. 2019;152:59-66. doi:10.1016/j.eplepsyres.2019.03.003 17. Mula M. Developments in depression in epilepsy: screening, diagnosis, and treatment. Expert Rev Neurother. 2019;19(3):269-276. doi:10.1080/14737175.2019.1585244 18. Kanner, AM. Depression and Epilepsy: A Review of Multiple Facets of Their Close Relation. Neurol Clin. 2009;27(4):865-80. 19. Elger CE, Johnston SA, Hoppe C. Diagnosing and treating depression in epilepsy. Seizure. 2017;44:184-193. doi:10.1016/j.seizure.2016.10.018 20. Janson MT, Bainbridge JL. Continuing Burden of Refractory Epilepsy. Ann Pharmacother. 2021;55(3):406-408. doi:10.1177/1060028020948056 21. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 2007;30:555-67 22. Piedad J, Rickards H, Besag FM, Cavanna AE. Beneficial and adverse effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations. CNS Drugs. 2012;26:319-35 23. Lopez-Gomez M, RamÃrez-Bermúdez J, Campilo C, Sosa AL, Espinola M, RuÃz I. Primidone is associated with interictal depression in patients with epilepsy. Epilepsy Behav. 2005;6:413-6 24. Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Epilepsy Behav. 2017;71:73-8. doi:10.1016/j.yebeh.2017.04.003 25. Patel S, Clancy M, Barry H. Psychiatric and psychosocial morbidity 1 year after epilepsy surgery [published online ahead of print, 2020 Nov 24]. Ir J Psychol Med. 2020;1-8. doi:10.1017/ipm.2020.114 26. Diagnostic and Statistical Manual of Mental Disorders. 5th edition: DSM-5. Arlington: American Psychiatric Association; 2015 27. McLintock K, Foy R, House A, Alderson SL. A policy of universal screening for depression: caution needed. BMJ. 2016;353:i2174. doi:10.1136/bmj.i2174 28. Micoulaud-Franchi JA, Barkate G, Trébuchon-Da Fonseca A. One step closer to a global tool for rapid screening of major depression in epilepsy: validation of the French NDDI-E. Epilepsy Behav. 2015;44:11-6 29. Al-Asmi A, Dorvlo AS, Burke DT. The detection of mood and anxiety in people with epilepsy using two-phase designs: experiences from a tertiary care centre in Oman. Epilepsy Res. 2012;98:174-81 30. Kanner AM. The treatment of depressive disorders in epilepsy: What all neurologists should know. Epilepsia. 2013;54:3-12 31. Michaelis R, Tang V, Wagner JL, Modi AC, Curt LaFrance W, Goldstein LH. Cochrane systematic review and meta-analysis of the impact of psychological treatments for people with epilepsy on health-related quality of life. Epilepsia. 2018;59:315-32. doi:10.1111/epi.13989 32. Michaelis R, Tang V, Goldstein LH, Reuber M, LaFrance WC, Lundgren T. Psychological treatments for adults and children with epilepsy: Evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. Epilepsia. 2018;59:1282-302. doi:10.1111/epi.14444. **ILAE recommendations on psychological treatments in epilepsy 33. Maguire MJ, Weston J, Singh J, Marson AG. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev 2014:CD010682. doi:10.1002/14651858.CD010682.pub2 34. Thomé-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav. 2007;10:417-25. doi:10.1016/j.yebeh.2007.01.004 35. Gilliam FG, Black KJ, Carter J. A Trial of Sertraline or Cognitive Behavior Therapy for Depression in Epilepsy. Ann Neurol. 2019;86(4):552-560. doi:10.1002/ana.25561 36. Hovorka J, Herman E, Nemcová I. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav. 2000;1:444-7). 37. Kühn KU, Quednow BB, Thiel M, Falkai P, Maier W, Elger CE. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav. 2003;4:674-9 38. Solmi M, Veronese N, Zaninotto L. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr. 2016;21(5):403-418. doi:10.1017/S1092852916000523 39. Fountoulakis KN, Karavelas V, Moysidou S. Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study. Pharmacopsychiatry. 2019;52(4):193-202. doi:10.1055/a-0695-9223 40. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology. 2005;65:1737-43. doi:10.1212/01.wnl.0000187118.19221.e4 41. Fakhoury TA, Miller JM, Hammer AE, Vuong A. Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open- label, multicentre, prospective study. Drugs Aging. 2008;25:955-62 42. Mazza M, Della Marca G, Di Nicola M, Martinotti G, Pozzi G, Janiri L. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav. 2007;10:397-401. doi:10.1016/j.yebeh.2007.01.003 43. Abou-Khalil BW. Update on Antiepileptic Drugs 2019. Continuum (Minneap Minn). 2019;25(2):508-536. doi:10.1212/CON.0000000000000715 44. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;62:345-54. doi:S0006-3223(06)01196-6 [pii] 10.1016/j.biopsych.2006.09.023 45. Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72-86. doi:10.1016/j.phrs.2016.02.014